Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States.
The last earnings update was 25 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Conatus Pharmaceuticals. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Conatus Pharmaceuticals's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Conatus Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Conatus Pharmaceuticals's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Conatus Pharmaceuticals's earnings growth to the Germany market average as no estimate data is available.
Unable to compare Conatus Pharmaceuticals's revenue growth to the Germany market average as no estimate data is available.
Unable to determine if Conatus Pharmaceuticals is high growth as no earnings estimate data is available.
Unable to determine if Conatus Pharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Conatus Pharmaceuticals's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Conatus Pharmaceuticals's finances.
The net worth of a company is the difference between its assets and liabilities.
Conatus Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Conatus Pharmaceuticals has no long term commitments.
This treemap shows a more detailed breakdown of
Conatus Pharmaceuticals's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Debt is not covered by short term assets, assets are -186.3x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Steven J. Mento, Ph.D., Co-founded Conatus Pharmaceuticals Inc. in 2005, has been its Chief Executive Officer and President since July 2005. Dr Mento served as an Acting Principal Financial Officer of Conatus Pharmaceuticals Inc. since March 31, 2017 until August 2017. He served as the President and Chief Executive Officer of IDUN Pharmaceuticals, Inc. from August 1997 to 2005. Dr. Mento joined Idun in 1997. From 1982 to 1992, he held various positions at American Cyanamid Company. His last position was Director of Viral Vaccine Research and Development at Lederle-Praxis Biologicals, a business unit of American Cyanamid Company. In January 1992, he joined Viagene Inc. as Vice President of Research and Development. He was responsible for directing the American Cyanamid's transition from basic research through initiation of the first company sponsored Phase I and Phase II clinical trials in the emerging field of gene therapy. He served as President of Chiron Viagene Inc. and Vice President of Chiron Corporation until August 1997. As President, he had overall responsibility for gene therapy research, product development, QA/ QC, GMP manufacturing as well as general administration functions at Chiron Viagene. Dr Mento served as a Research Assistant Professor of Medicine and Microbiology at Mount Sinai School of Medicine from 1980 to 1982 before commencing his career in industry. Dr. Mento has over twenty years of combined experience in the biotechnology and pharmaceutical industry, ten of which served as President and Chief Executive Officer. He has been Chairman of Hawaii Biotech, Inc. since April 2007 and has been its Director since December 14, 2006. Dr. Mento served as the Chairman of Conatus Pharmaceuticals Inc. since July 2005 until December 2012. Dr. Mento served as Independent Director of Sangamo Therapeutics, Inc. since May 24, 2005 until June 11, 2019. He has been a Director of Conatus Pharmaceuticals Inc. since July 2005. He serves as a Director of Biotechnology Industry Organization (BIO). He serves on the Boards of BIOCOM, BIOCOM Institute, BIO Emerging Company Section Governing Body, the BIO Health Section Governing Body, Grannus BioSciences, UCSD-Division of Biological Sciences Board of Advisors, Donald P. Shiley BioScience Center at SDSU Scientific Advisory Board and UCSD Bannister Family House. He served as a Director of IDUN Pharmaceuticals, Inc. from August 1997 to 2005. From 1986 to 1992, he was a Member of the World Health Organization (WHO) Consultative Group on Poliomyelitis Vaccines. In October 1995, Chiron Corporation acquired Viagene Inc., and renamed American Cyanamid as Chiron Viagene Inc. Dr. Mento holds Bachelor of Arts, Master of Science and Ph.D. degrees in Microbiology from Rutgers University. He did his post-doctoral fellowship in somatic cell genetics at the University of Toronto.
Steven's compensation has increased whilst company is loss making.
Steven's remuneration is higher than average for companies of similar size in Germany.
Executive Director of Investor Relations & Corporate Communications
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Conatus Pharmaceuticals board of directors is about average.
Board of Directors
Hal Van Wart
Member of Advisory Board
Member of Advisory Board
Member of Advisory Board
Additional Independent Director
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidate includes Emricasan, an orally active caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for portal hypertension; for liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company is also developing CTS-2090, an orally active inhibitor of caspase 1, which is in preclinical development stage for treating chronic diseases involving inflammasome pathways. The company has a collaboration agreement with Novartis to conduct three Phase IIb clinical trials. Conatus Pharmaceuticals Inc. was founded in 2005 and is headquartered in San Diego, California.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.